July 20, 2020

CNBC: Moderna shares jump as much as 16% after company says its coronavirus vaccine trial produced ‘robust’ immune response

  • Science4Data Article Insights
Book a Demo
  • This field is for validation purposes and should be left unchanged.
Science4Data Article Insights

https://www.cnbc.com/2020/07/14/moderna-says-its-coronavirus-vaccine-trial-produced-robust-immune-response-in-all-patients.html

Moderna shares jump as much as 16% after company says its coronavirus vaccine trial produced 'robust' immune response

2020-07-14 00:00:00, Berkeley Lovelace Jr., CNBC

Content Categorization
/Health/Health Conditions/Infectious Diseases
/Health/Medical Facilities & Services/Medical Procedures
/Health/Public Health
/Law & Government/Public Safety

Word Count:
593

Words/Sentence:
24

Reading Time:
5.93 min

Reading Quality:
Advanced

Readability:
16th or higher

Media Sentiment
Proprietary sentiment analysis on both the headline and body text of the article. Sentiment scores range from -1 (very negative sentiment) to 1 (very positive sentiment).
RCS Analysis
Relative scoring for Risk, Crisis, and Security language within the article.
Risk Score
Scoring based on the composite risk, security and crisis language within an article compared to a baseline of historic analysis across thousands of diverse articles.
PESTEL Scope
Analysis of article orientation across the PESTEL macro-environmental analysis framework. Learn more about PESTEL.
Entity Word Cloud
Key people, places, organizations and events referenced in the article, weighted by frequency and colored based on contextual sentiment.
Auto Summary
Condensing key features of the article based on salience analysis. Helpful for “gisting” the article in a time crunch.

Moderna's shares soared after the company said its potential vaccine to prevent Covid-19 produced a "robust" immune response in all 45 patients in its early stage human trial, according to newly released data published Tuesday evening in the peer-reviewed New England Journal of Medicine.

All 45 patients produced neutralizing antibodies, which scientists believe is important for building immunity and provided more promising data that the vaccine may give some protection against the coronavirus.

The trial will enroll 30,000 participants across 87 locations, according to ClinicalTrials.gov. Participants in the experimental arm will receive a 100 microgram dose of the potential vaccine on the first day and another 29 days later.

After two vaccinations, the vaccine elicited a "robust" immune response in all participants in all dose cohorts, Moderna said.

The effort by Moderna is one of several working on a potential vaccine for Covid-19, which has infected more than 13 million people and killed at least 573,200 across the globe as of Tuesday, according to data compiled by Johns Hopkins University.

Keywords
Biotechnology, business news, Epidemics, Health care industry, Moderna Inc, U.S. Economy, Coronavirus, Pandemics, Disease outbreaks, Politics, Biotech and Pharmaceuticals, Breaking News: Business

Share

Interested in Learning More?

Article Analysis is at the foundation of powerful media monitoring and insights. Learn what you can build with powerful curated search engines, real-time listening and trend analysis on the topics, markets and companies critical to your organization.